US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.53

-0.0900-2.49%

Post-market: 3.530.00000.00%16:28 EDT

Volume:1.04M

Turnover:3.64M

Market Cap:110.45M

PE:-0.85

High:3.61

Open:3.58

Low:3.35

Close:3.62

52wk High:49.25

52wk Low:3.35

Shares:31.29M

Float Shares:18.39M

Volume Ratio:1.35

T/O Rate:5.64%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.1300

EPS(LYR):-2.8503

ROE:-59.21%

ROA:-37.36%

PB:0.50

PE(LYR):-1.24

Loading ...

Overview Company News Filings

Spyre Therapeutics 250M share Spot Secondary; re-offered at $85.00

Guggenheim starts Ovid Therapeutics with a Buy on OV329 potential

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

CAMP4 Therapeutics Initiated at Outperform by Oppenheimer

EXACT Therapeutics Issues Detailed Guidance Ahead of Euronext Growth Delisting

Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026

Aprea Therapeutics to Present at October Conferences

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

Monte Rosa Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Oppenheimer Initiates Coverage on CAMP4 Therapeutics With Outperform Rating, $15 Price Target

MT Newswires Live

AstraZeneca completes $2B equity investment in Summit Therapeutics

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

Crispr Therapeutics: Favorable Early zugo-cel Data in Systemic Sclerosis Support Buy Rating; $82 Price Target Reiterated

Sarepta Therapeutics: ELEVIDYS Data and Revenue Trends Support Continued Sell Rating with Unchanged $5 Price Target

Percheron Therapeutics Plans Issue of 75 Million Performance Restricted Stock Units

Chimeric Therapeutics Discloses Final Director Interest as Lesley Russell Departs Board

Chimeric Therapeutics Announces Departure of Director Without Shareholdings

Chimeric Therapeutics Names New Director, Grants 500,000 Options

ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LENZ/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":3.53,"timestamp":1791489600000,"preClose":3.62,"halted":0,"volume":1036984,"hourTrading":{"tag":"盘后","latestPrice":3.53,"preClose":3.53,"latestTime":"16:28 EDT","volume":19933,"amount":70363.2807035,"timestamp":1791491287515,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.024861878453038756,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Post-Mkt","change":-0.09,"latestTime":"10-08 16:35:45 EDT","open":3.58,"high":3.61,"low":3.35,"amount":3637232,"amplitude":0.071823,"askPrice":3.84,"askSize":100,"bidPrice":3.42,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791504000000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":3.62,"preHourTrading":{"tag":"盘前","latestPrice":3.65,"preClose":3.62,"latestTime":"08:43 EDT","volume":1305,"amount":4794.754005,"timestamp":1791463387281,"change":0.03,"changeRate":0.008287,"amplitude":0.017818},"postHourTrading":{"tag":"盘后","latestPrice":3.53,"preClose":3.53,"latestTime":"16:28 EDT","volume":19933,"amount":70363.2807035,"timestamp":1791491287515,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.349693,"impliedVol":2.4236,"impliedVolPercentile":0.8406},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":1.349693,"shares":31289969,"dividePrice":0,"high":3.61,"amplitude":0.071823,"preClose":3.62,"low":3.35,"week52Low":3.35,"pbRate":"0.50","psRate":"5.14","week52High":49.25,"institutionHeld":0,"latestPrice":3.53,"committee":-0.333333,"eps":-4.13,"divideRate":0,"volume":1036984,"delay":0,"ttmEps":-4.13,"open":3.58,"prevYearClose":16,"prevWeekClose":3.58,"prevMonthClose":3.84,"prevQuarterClose":3.84,"fiveDayClose":3.79,"twentyDayClose":4.72,"sixtyDayClose":4.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-10-07","current":-0.854722,"percent":0.99187,"low":-26.69966,"twenty":-16.20413,"median":-9.539848,"eighty":-3.680353,"high":-0.892723,"avg":-10.226631,"sd":6.317992,"marketCap":119083099},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798},{"date":"2026-08-28","current":-1.19944,"twenty":-16.297238,"median":-9.783769,"eighty":-5.425546,"marketCap":151131849},{"date":"2026-09-04","current":-1.453791,"twenty":-16.251993,"median":-9.763078,"eighty":-5.336455,"marketCap":183180599},{"date":"2026-09-11","current":-1.176997,"twenty":-16.223282,"median":-9.734689,"eighty":-5.236314,"marketCap":148304018},{"date":"2026-09-18","current":-1.029873,"twenty":-16.218091,"median":-9.676907,"eighty":-3.875061,"marketCap":129766016},{"date":"2026-09-25","current":-0.927633,"twenty":-16.212803,"median":-9.639455,"eighty":-3.772744,"marketCap":116883675},{"date":"2026-10-02","current":-0.945089,"twenty":-16.204574,"median":-9.574004,"eighty":-3.700206,"marketCap":119083099},{"date":"2026-10-07","current":-0.945089,"twenty":-16.20413,"median":-9.539848,"eighty":-3.680353,"marketCap":119083099}],"updateTime":1791490605332},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673082920","title":"Spyre Therapeutics 250M share Spot Secondary; re-offered at $85.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2673082920","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673082920?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:20","pubTimestamp":1791235226,"startTime":"0","endTime":"0","summary":"Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the proposed offering. Published first on TheFly...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-250m-share-spot-secondary-re-offered-at-85-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-250m-share-spot-secondary-re-offered-at-85-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673906084","title":"Guggenheim starts Ovid Therapeutics with a Buy on OV329 potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2673906084","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673906084?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:30","pubTimestamp":1791232233,"startTime":"0","endTime":"0","summary":"As previously reported, Guggenheim initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $7 price target OV329, the company’s lead a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guggenheim-starts-ovid-therapeutics-with-a-buy-on-ov329-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guggenheim-starts-ovid-therapeutics-with-a-buy-on-ov329-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","BK4007","OVID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673780081","title":"Spyre Therapeutics Announces Proposed Public Offering of its Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2673780081","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673780081?lang=en_us&edition=fundamental","pubTime":"2026-10-06 04:01","pubTimestamp":1791230460,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct.  05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374974/0/en/spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673866089","title":"CAMP4 Therapeutics Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673866089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673866089?lang=en_us&edition=fundamental","pubTime":"2026-10-06 01:45","pubTimestamp":1791222300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CAMP/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673700125","title":"EXACT Therapeutics Issues Detailed Guidance Ahead of Euronext Growth Delisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673700125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673700125?lang=en_us&edition=fundamental","pubTime":"2026-10-05 21:07","pubTimestamp":1791205677,"startTime":"0","endTime":"0","summary":"EXACT Therapeutics AS ( ($DE:56F) ) just unveiled an update. EXACT Therapeutics AS has released additional practical information for shareholders a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/exact-therapeutics-issues-detailed-guidance-ahead-of-euronext-growth-delisting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/exact-therapeutics-issues-detailed-guidance-ahead-of-euronext-growth-delisting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AS","LENZ","BK4202","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673707693","title":"Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673707693","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673707693?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:30","pubTimestamp":1791203400,"startTime":"0","endTime":"0","summary":"LONDON and GAITHERSBURG, Md., Oct.  05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374552/0/en/autolus-therapeutics-to-present-longer-term-follow-up-data-from-carlysle-trial-at-the-american-college-of-rheumatology-convergence-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","IE0031619046.USD","BK4539","CRS","LU0985320562.USD","LU2065731478.USD","BK4107","IE00B66KJ199.SGD","BK4117","CAR","IE0000B7K699.USD","LENZ","IE000MB6IJN5.SGD","LU0963586101.USD","BK4585","IE00B19Z4B17.USD","BK4588","IAK","LU1699723380.USD","IE000F7OJYX1.SGD","AFG","ACR","BK4006","XAR","BK4007","BK4139","IE000BZT7R73.USD","BK4022","PYZ","IE00B7SZL793.SGD","IE000SO60NU8.SGD","LU1571399168.USD","BK4187","BK4230","ALL","LU2355687059.USD","IE000WAW04H5.SGD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673664707","title":"Aprea Therapeutics to Present at October Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2673664707","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673664707?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:30","pubTimestamp":1791203400,"startTime":"0","endTime":"0","summary":"Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15)DOYLESTOWN, Pa., Oct.  05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374539/0/en/aprea-therapeutics-to-present-at-october-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702771","title":"Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702771","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702771?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201600,"startTime":"0","endTime":"0","summary":"Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374474/18623/en/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mar002-a-potential-best-in-disease-investigational-therapy-for-the.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","ENDO","FFOX","KBWY","PTH","BK4585","GNOM","BK4139","LFSC","BK4535","LU0889565916.HKD","BK4539","GNMX","HELX","BK4007","PK","BK4183","BK4551","LU0320765992.SGD","LENZ","EKG","BK4181","GH","BK4588","BK4218","BK4196","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702726","title":"Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702726","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702726?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201600,"startTime":"0","endTime":"0","summary":"~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill platform technology ~SAN JOSE, Calif., Oct.  05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Na","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374470/0/en/rani-therapeutics-announces-acceptance-into-u-s-fda-s-emerging-technology-program-etp.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LENZ","BK4139","BK4539","LABU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702386","title":"Monte Rosa Therapeutics Price Target Maintained with a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702386","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702386?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:42","pubTimestamp":1791200520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLUE/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704144","title":"Oppenheimer Initiates Coverage on CAMP4 Therapeutics With Outperform Rating, $15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704144","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704144?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:18","pubTimestamp":1791199102,"startTime":"0","endTime":"0","summary":"CAMP4 Therapeutics (CAMP) has an average rating of buy and mean price target of $9.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673044487","title":"AstraZeneca completes $2B equity investment in Summit Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2673044487","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673044487?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:12","pubTimestamp":1791198767,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) announced the successful closing of AstraZeneca’s (AZN) strategic equity investment in Summit. The equity investment wil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-completes-2b-equity-investment-in-summit-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-completes-2b-equity-investment-in-summit-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZN","LU2237443622.USD","LU2089984988.USD","BK4139","LU1829250122.USD","LU0320765992.SGD","LU2462157665.USD","LU2237443382.USD","LU2468319806.SGD","SMMT","BK4588","LU0058720904.USD","LU0289739699.SGD","LU2237443465.HKD","LU2237443549.SGD","LU1267930573.SGD","AZNH","LU0029864427.USD","LU2488822045.USD","BK4585","LU0432979614.USD","LU2237443895.HKD","LU0109394709.USD","LU0889565916.HKD","LU2236285917.USD","LU2417539215.USD","LU2456880835.USD","IE00B3T34201.USD","LU2237443978.SGD","LU0708994859.HKD","BK4568","BK4007","LU0128525929.USD","LU0310800379.SGD","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704197","title":"Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704197","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704197?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:05","pubTimestamp":1791198300,"startTime":"0","endTime":"0","summary":"ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of func","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374418/0/en/alterity-therapeutics-presents-new-analyses-of-ath434-phase-2-data-in-multiple-system-atrophy-at-the-2026-international-congress-of-parkinson-s-disease-and-movement-disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU2125909916.SGD","LU2211815571.USD","LU0154245756.USD","LENZ","LU0728928796.USD","MSA","CSF","LU1815336091.USD","BK4139","LU0757428866.USD","LU2125909759.SGD","ATHE","LU1923622291.USD","BK4539","BK4007","BK4143","LU0154245673.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704362","title":"Crispr Therapeutics: Favorable Early zugo-cel Data in Systemic Sclerosis Support Buy Rating; $82 Price Target Reiterated","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704362?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:55","pubTimestamp":1791197746,"startTime":"0","endTime":"0","summary":"Gil Blum, an analyst from Needham, maintained the Buy rating on Crispr Therapeutics AG. The associated price target remains the same with $82.00. G...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/crispr-therapeutics-favorable-early-zugo-cel-data-in-systemic-sclerosis-support-buy-rating-82-price-target-reiterated-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/crispr-therapeutics-favorable-early-zugo-cel-data-in-systemic-sclerosis-support-buy-rating-82-price-target-reiterated-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704368","title":"Sarepta Therapeutics: ELEVIDYS Data and Revenue Trends Support Continued Sell Rating with Unchanged $5 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704368","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704368?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:55","pubTimestamp":1791197737,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor has reiterated their bearish stance on SRPT stock, giving a Sell rating on September 28. Mitchell Kapoor ha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sarepta-therapeutics-elevidys-data-and-revenue-trends-support-continued-sell-rating-with-unchanged-5-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sarepta-therapeutics-elevidys-data-and-revenue-trends-support-continued-sell-rating-with-unchanged-5-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673770772","title":"Percheron Therapeutics Plans Issue of 75 Million Performance Restricted Stock Units","url":"https://stock-news.laohu8.com/highlight/detail?id=2673770772","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673770772?lang=en_us&edition=fundamental","pubTime":"2026-10-05 14:20","pubTimestamp":1791181254,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Percheron Therapeutics ( ($AU:PER) ). Percheron Therapeutics has notified the ASX of a proposed issue of up to ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-plans-issue-of-75-million-performance-restricted-stock-units?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/percheron-therapeutics-plans-issue-of-75-million-performance-restricted-stock-units?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673777254","title":"Chimeric Therapeutics Discloses Final Director Interest as Lesley Russell Departs Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2673777254","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673777254?lang=en_us&edition=fundamental","pubTime":"2026-10-05 13:47","pubTimestamp":1791179238,"startTime":"0","endTime":"0","summary":"An announcement from Chimeric Therapeutics Ltd. ( ($AU:CHM) ) is now available. Chimeric Therapeutics has announced that Lesley Russell ceased to b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-discloses-final-director-interest-as-lesley-russell-departs-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-discloses-final-director-interest-as-lesley-russell-departs-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673777992","title":"Chimeric Therapeutics Announces Departure of Director Without Shareholdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2673777992","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673777992?lang=en_us&edition=fundamental","pubTime":"2026-10-05 13:38","pubTimestamp":1791178691,"startTime":"0","endTime":"0","summary":"An announcement from Chimeric Therapeutics Ltd. ( ($AU:CHM) ) is now available. Chimeric Therapeutics has announced that director Bradley Glover ce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-announces-departure-of-director-without-shareholdings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-announces-departure-of-director-without-shareholdings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673919777","title":"Chimeric Therapeutics Names New Director, Grants 500,000 Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2673919777","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673919777?lang=en_us&edition=fundamental","pubTime":"2026-10-05 13:38","pubTimestamp":1791178683,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Chimeric Therapeutics Ltd. ( ($AU:CHM) ). Chimeric Therapeutics Limited has appointed Rebecca McQualter as a di...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-names-new-director-grants-500000-options?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-names-new-director-grants-500000-options?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776492","title":"ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776492","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776492?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:07","pubTimestamp":1791155252,"startTime":"0","endTime":"0","summary":"Australian shares are poised to rise on Monday after oil prices climbed as attacks claimed by Yemen's Iran-backed Houthis on Saudi Aramco sites raised concerns about potential disruptions to crude production.Oil prices were also supported after the Organization of the Petroleum Exporting Countries decided to keep its November output targets unchanged, limiting expectations for additional supply and helping keep Brent crude above $100 a barrel amid the Iran war.On Oct. 2, the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average rose 0.7%, 1.2%, and 0.5%, respectively.In the macroeconomy, Australia's private-sector growth slowed in September as weaker new business weighed on services activity, prompting a resumption of job cuts while inflationary pressures intensified, according to a monthly survey by S&P Global released Monday.In corporate news, CSL  entered a partnership with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class therapy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IIGF.AU","QRE.AU","STW.AU","IMLC.AU","BEAR.AU","BBOZ.AU","BK4139","OZR.AU","E200.AU","VAS.AU","EIGA.AU","BK7067","BK7508","BK4007","OZF.AU","BK4539","CMM.AU","GEAR.AU","GIVE.AU","ZYAU.AU","LENZ","QFN.AU","XKO.AU","IOZ.AU","BK7511","BK7501","CSL.AU","VAP.AU","BK7104","SLF.AU","XJO.AU","IISV.AU","XAO.AU","DACE.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}